Skip to main content
Premium Trial:

Request an Annual Quote

Affy Says Sales Surpassed $100M in Q4 04, a 17-Percent Increase

NEW YORK, Jan. 5 (GenomeWeb News) - Affymetrix estimates it has generated more than $100 million in product-related revenues for the fourth quarter of 2004, a record for the company, the firm said today.


This represents a 17-percent increase over the $85.3 million in product-related revenues recorded for the same quarter a year ago.


Affymetrix also said it has $10 million worth of orders for products it plans to release within the next six months, including new SNP-genotyping arrays and automated instrumentation.


The company will release its formal financial results on Jan. 26 after the stock market closes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more